| 摘要: |
| 神经母细胞瘤是儿童常见实体瘤之一,其中难治性高危亚型因复发率高、治疗方案有限、预后差等特点,成为儿科肿瘤
治疗领域的难点。那西妥单抗作为靶向神经节苷脂( GD2) 的单克隆抗体,其联合PD-1 抑制剂纳武利尤单抗的双免疫治疗方
案,为该类患儿带来了新的治疗机遇,但二者联合使用时不良反应复杂,且存在超说明书用药情况,临床用药安全性与有效性需
专业药学支持。本研究旨在通过分析1 例难治性高危神经母细胞瘤患儿的药学监护实践,探讨那西妥单抗联合纳武利尤单抗
治疗中的药学监护重点、干预策略及实践价值,为临床安全合理用药提供参考。 |
| 关键词: 神经母细胞瘤 药学监护 药学干预 不良反应管理 超说明书用药 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2026.07.004 |
|
| 基金项目:深圳市罕见病临床医学研究中心项目基金,编号LCYSSQ20220823091402005;深圳市“医疗卫生三名工程”项目基金,编号
SZSM202311022。 |
|
| Off-Label Drug-Use Management and Full-Course Pharmaceutical Care for Children with Refractory High-Risk Neuroblastoma Treated with Naxitamab Combined with Nivolumab |
| Zhong Gong, Mo Shu, Liang Weiling, Zhou Li, Zhuo Yubo |
| ((The University of Hong Kong-Shenzhen Hospital, Shenzhen
Clinical Research Center for Rare Diseases, Guangdong Shenzhen 518053, China)) |
| Abstract: |
| Neuroblastoma is a prevalent solid tumor in children, with the refractory high-risk subtype representing a formidable
therapeutic challenge due to high recurrence rates, scarce treatment options, and dismal prognosis. The combination of naxitamab, an
anti-GD2 monoclonal antibody, and nivolumab, a PD-1 inhibitor, constitutes a promising dual immunotherapy regimen for such patients.
However, the concurrent use of these agents entails complex adverse drug reactions and frequently involves off-label indications, thereby
requiring specialized pharmaceutical support to guarantee clinical safety and efficacy. This study aims to analyze the pharmacological
care of a child with refractory high-risk neuroblastoma, and explore the key points, intervention strategies and practical value of
pharmacological monitoring in the treatment with nivolumab combined with atezolizumab, which could provide reference for the safe and
rational drug use. |
| Key words: neuroblastoma pharmaceutical care pharmaceutical intervention adverse drug reaction management off-label drug use |
